The Role of Animal Models in Evaluating Reasonable Safety and Efficacy for Human Trials of Cell-Based Interventions for Neurologic Conditions

Progress in regenerative medicine seems likely to produce new treatments for neurologic conditions that use human cells as therapeutic agents; at least one trial for such an intervention is already under way. The development of cell-based interventions for neurologic conditions (CBI-NCs) will likely...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Cerebral Blood Flow & Metabolism 2009-01, Vol.29 (1), p.1-9
Hauptverfasser: Regenberg, Alan, Mathews, Debra JH, Blass, David M, Bok, Hilary, Coyle, Joseph T, Duggan, Patrick, Faden, Ruth, Finkel, Julia, Gearhart, John D, Hillis, Argye, Hoke, Ahmet, Johnson, Richard, Johnston, Michael, Kahn, Jeffrey, Kerr, Douglas, King, Patricia, Kurtzberg, Joanne, Liao, S Matthew, McDonald, John W, McKhann, Guy, Nelson, Karin B, Rao, Mahendra, Siegel, Andrew W, Smith, Kirby, Solter, Davor, Song, Hongjun, Sugarman, Jeremy, Vescovi, Angelo, Young, Wise, Greely, Henry T, Traystman, Richard J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Progress in regenerative medicine seems likely to produce new treatments for neurologic conditions that use human cells as therapeutic agents; at least one trial for such an intervention is already under way. The development of cell-based interventions for neurologic conditions (CBI-NCs) will likely include preclinical studies using animals as models for humans with conditions of interest. This paper explores predictive validity challenges and the proper role for animal models in developing CBI-NCs. In spite of limitations, animal models are and will remain an essential tool for gathering data in advance of first-in-human clinical trials. The goal of this paper is to provide a realistic lens for viewing the role of animal models in the context of CBI-NCs and to provide recommendations for moving forward through this challenging terrain.
ISSN:0271-678X
1559-7016
DOI:10.1038/jcbfm.2008.98